Work

Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.6_suppl.333

Authors: Othon Iliopoulos, Eric Jonasch, Frede Donskov, Vivek Narayan, Benjamin Louis Maughan, Stephane Oudard, Tobias Else, Jodi K. Maranchie, Sarah J. Welsh, Sanjay Thamake, Rodolfo F. Perini, Eric Kristopher Park, W. Marston Linehan, Ramaprasad Srinivasan, W. Kimryn Rathmell

Institutions: Harvard University, Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, Aarhus University Hospital, University of Pennsylvania, University of Utah, Hôpital Européen Georges-Pompidou, University of Michigan, University of Pittsburgh, Cambridge University Hospitals NHS Foundation Trust, Merck & Co., Inc., Rahway, NJ, USA (United States), National Cancer Institute, Center for Cancer Research, Vanderbilt University

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3134205121

Cites:

Cited by: 3

Related to: 10